Moreover, it was demonstrated that treating U251MG cells with both erlotinib and the alkaloid oxymatrine significantly lowered p-EGFR, p-Akt and p-mTOR levels, and inhibited cancer cell proliferation, compared to erlotinib or oxymatrine monotherapies [100]. This evidence concerns the gene EGFR and cancer.